drugset / Trial / NCT06506955
Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a nonrandomized, open-label, multicenter rollover study for patients who received futibatinib as monotherapy or as combination therapy in a Taiho-sponsored futibatinib study.
Timeline
- Start
- 2024-10-01
- Primary completion
- 2027-04
- Completion
- 2027-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fulvestrant | Small molecule | — | — |
| Subject | Futibatinib | Small molecule | — | Oral |